IL37 and psoriasis: In psoriasis, MSC-derived EVs show the most consistent therapeutic signal and the broadest mechanisms, attenuating dendritic-cell IL-23 production, suppressing keratinocyte STAT3 signaling, and (topically) limiting complement/NETosis.